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This prospective, 6-week, multicenter, double-blind
study examined the benefits of initiating treatment with
combination valsartan/hydrochlorothiazide (HCTZ) com-
pared with initial valsartan monotherapy for 648 patients
with stage-1 or stage-2 hypertension (age¼52.6±10
years; 54% male; baseline blood pressure (BP)¼161/
98mmHg, 32% stage 1). Patients were randomized to
valsartan 80mg (V-low), valsartan 160mg (V-high) or
valsartan/HCTZ 160/12.5mg (V/HCTZ), and electively
titrated after weeks 2 and 4 to the next dosage level
(maximum dose valsartan/HCTZ 160/25mg) if BP remained
4140/90mmHg. At end of the study, patients initiated
with V/HCTZ required less titration steps compared with
the initial valsartan monotherapy groups (63 vs 86%
required titration by study end, respectively) and reached
the target BP goal of o140/90mmHg in a shorter period
of time (2.8 weeks) (Po0.0001) vs V-low (4.3 weeks) and
V-high (3.9 weeks). Initial combination therapy was also
associated with higher BP control rates and greater
reductions in both systolic and diastolic BP from baseline
(63%,  27.7±13/–15.1±8mmHg) compared with V-low
(46%,  21.2±13/ 11.4±8mmHg, Po0.0001) or V-high
(51%,  24.0±13/ 12.0±10mmHg, Po0.01). Overall and
drug-related AEs were mild to moderate and were similar
between V/HCTZ (53.1 and 14.1%, respectively) and the
two monotherapy groups, V-low (50.5 and 13.8%) and
V-high (50.7 and 11.8%). In conclusion, initiating therapy
with a combination of valsartan and low-dose HCTZ
results in early, improved BP efficacy with similar toler-
ability as compared with starting treatment with a low or
higher dose of valsartan for patients with stage-1 and
stage-2 hypertension.
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Introduction
Based on recent national surveys, blood pressure
(BP) control rates for patients with hypertension
continue to be low and improvements in therapeutic
management strategies are required in order for
more patients to reach target BP goals.
1 It is well
recognized that most patients with hypertension
will require two or more antihypertensive agents for
effective BP control.
2 Rational combinations of
antihypertensive agents as single-pill formulations
are readily available, but their use remains low
primarily due to health care providers who are
reluctant to intensify therapy.
3 Earlier and more
frequent use of combination therapy in the manage-
ment of hypertension would greatly improve BP
control rates. The FDA recently approved single-pill
combinations of an angiotensin-receptor blocker (ARB)
and hydrochlorothiazide (HCTZ),
4,5 and combinations
of ARB with amlodipine for initial treatment of hyper-
t e n s i o ni np a t i e n t sw h o s eB Pw o u l dn o tb ec o n t r o l l e d
on monotherapy alone. The initial therapy indication
did not stipulate the BP level at which combination
therapy should be initiated, but current treatment
guidelines suggest that use of combination therapy
should be guided by baseline BP and the cardio-
vascular (CV) risk status of the patient.
6,7
For patients unresponsive to valsartan or low-
dose HCTZ monotherapy, addition of the other agent
has resulted in further reductions of BP, without
increase in adverse events (AEs).
8–11 The excellent
tolerability and complementary BP-lowering effects
of this combination makes it an ideal agent for initial
use in patients with stage-1 and stage-2 hyper-
tension. The primary arguments against initiating
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sion are based on clinical need and safety concerns.
Initial combination therapy for patients whose BP
could be controlled by monotherapy, may lead to
excessive drops in BP and thus increase the risk for
hypotension-related AEs. Common practice is to
initiate treatment with low-dose monotherapy and
up-titrate to higher dose every 4 weeks. There has
been no prospective study that has evaluated initial
combination therapy using valsartan and HCTZ as
compared with monotherapy when evaluating BP
control rates and time to BP control in patients with
primary essential hypertension without additional
CV risk factors. Based on the need for improved BP
control strategies, we conducted a study to deter-
mine the efficacy of initial combination therapy
with valsartan and HCTZ for patients with stage-1 or
stage-2, uncomplicated hypertension as compared
with initiating therapy with low (80mg) or higher
dose (160mg) valsartan monotherapy.
Patients and methods
Patients
The study enrolled patients X18 years of age with a
documented diagnosis of hypertension defined as
mean sitting systolic BP (MSSBP) X150 and
o180mmHg and mean sitting diastolic BP
(MSDBP) X90 and o110mmHg. Patients were
excluded if they had severe hypertension, known
or suspected secondary hypertension, previous
myocardial infarction, stroke or other CV complica-
tions, severe hepatic disease, history of malignancy,
or allergy/hypersensitivity to valsartan or HCTZ.
Women of childbearing potential were eligible if
pregnancy testing was negative. The protocol was
approved by all relevant ethics committees and all
patients provided written informed consent.
Study design
This was a 6-week, multicenter, randomized, dou-
ble-blind, parallel-group study conducted across 78
US centres. Following a 14- to 28-day washout
period, during which all pre-study antihypertensive
medications, if used, were discontinued; eligible
patients entered a 6-week, double-blind period
during which they received valsartan (80mg),
valsartan (160mg) or valsartan (160mg)/HCTZ
(12.5mg) for 2 weeks according to the randomiza-
tion scheme (Figure 1). The three groups were
referred to as valsartan-low (V-low), valsartan-high
(V-high) and the combination group, valsar-
tanþHCTZ (V/HCTZ), respectively. At the end of
this period, patients whose BP was uncontrolled
(MSSBPX140mmHg or MSDBPX90mmHg) were
titrated to the next dosage level (valsartan 160mg,
valsartanþHCTZ 160/12.5mg, or valsartanþ
HCTZ 160/25mg respectively in the 3 groups) for
2 weeks. Patients whose BP was uncontrolled
(MSSBPX140mmHg or MSDBPX90mmHg) at
week 4, were titrated to the next dosage level
(valsartanþHCTZ 160/12.5mg or valsartanþHCTZ
160/25mg) in the V-low and V-high groups while
V/HCTZ was maintained at the dose of 160/25mg
(Figure 1). Patients achieving a target BP goal of
o140/90mmHg were maintained at the dose level
to which they responded during the double-blind
treatment phase. Patients were instructed to take
their medication in the morning at the same time
each day. To maintain the blinded nature of
the study, patients on monotherapy received one
placebo pill along with a pill of active therapy.
Concomitant therapy with the following medica-
tions was prohibited: other ARBs, angiotensin-
converting enzyme (ACE) inhibitors, b-adrenergic
antagonists, calcium-channel blockers, any other anti-
hypertensive(s), and potassium-sparing diuretics (for
example, spironolactone, triamterene or amiloride),
anti-arrhythmic drugs, nitrates, a-adrenergic anta-
gonists and digitalis glycosides. Drugs to treat erectile
dysfunction were permitted, except within 24h (silde-
nafil, vardenafil) and 48h (tadalafil) of study visits.
Outcomes
The objectives of this trial were to compare the
proportion of patients achieving BP control and
the change in MSSBP and MSDBP from baseline
between antihypertensive treatment regimens, in-
itiated with valsartan (80mg), valsartan (160mg)
or valsartanþHCTZ (160/12.5mg). The primary
efficacy variable was change in MSSBP from base-
line to week 4. Secondary outcomes included time
to achieve BP goal (defined as the first achievement
of the target BP goal of o140mmHg systolic BP and
o90mmHg diastolic BP during the 6-week period),
in all patients and in patients with stage-1 (SBP
140–159mmHg or DBP 90–99mmHg) and stage-2
hypertension (SBPX160mmHg or DBPX100mmHg).
During study visits, BP and heart rate measure-
ments were obtained and AEs that occurred since
the last study visit were recorded. Any unfavourable
medical occurrence, regardless of its suspected
cause, was considered an AE. The frequency and
severity of AEs, as well as their relationship to study
medication, were summarized.
Statistical methods
The sample size was based on the comparison of
treatment effects between patients initiated with
valsartan (80mg) and those initiated with valsartan
(160mg) with respect to the primary efficacy vari-
able, change in MSSBP from baseline to week 4.
Assuming a between-group difference in change in
mean MSSBP from baseline to week 4 of the double-
blind treatment period of 4.0 (s.d.¼14mmHg),
it was projected that 216 patients per treatment
group (a total sample size of 648 randomized
patients) would provide an 80% power to detect a
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(two-sided). To control for overall type-I error, a
stepwise testing procedure for the primary analyses
was adopted. The primary efficacy comparison
between the V-low group and the V-high group
was tested first. Primary efficacy comparison be-
tween V-low and V/HCTZ was performed only if test
result from V-low group vs V-high group was
statistically significant.
The safety population consisted of all randomized
subjects who received at least one dose of the study
medication. All efficacy analyses were performed
using the intent-to-treat population (all randomized
patients who received at least one dose of the study
drug and had a valid baseline and at least one valid
post-baseline assessment of the primary efficacy
variable). For analysis of efficacy data, a last-
observation carried forward (LOCF) method was
used. An analysis of covariance model was used
with baseline measurement as a covariate and
treatment as a factor in the model for analyses of
all continuous primary and secondary efficacy
variables. The primary time point for the analyses
was week 4. w
2-Tests were used for categorical
variables (the number and percentage of patients
achieving BP goal). The time to achieving BP control
was analysed by Kaplan–Meier estimates and
was presented for each treatment arm. Wilcoxon
tests were used to test the differences between
treatments.
Results
Patient disposition
From a total of 1413 patients screened for the study,
652 patients were enrolled in the double-blind
phase and randomly assigned to one of the three
treatment groups: V-low (n¼218), V-high (n¼221)
and V/HCTZ (n¼213). Most patients who partici-
pated in the double-blind treatment phase were
Caucasian (67%), with a mean age of 53 years and
almost 88% of the patients o65 years of age. Most of
the patients were not diabetic (87%), but a majority
had the metabolic syndrome (57%). At least half of
all patients enrolled were on previous antihyperten-
sive therapy. Overall, demographic characteristics
were similar between the treatment groups (Table 1).
Of the 652 patients randomized into the study,
51 withdrew prior to completing their participation:
V-low, n¼17; V-high, n¼17 and V/HCTZ, n¼17. The
most common reasons for patient withdrawal were
AEs, unsatisfactory therapeutic effect and patient
withdrawal of consent. A total of four patients
(1 patient in the V-high group and 3 patients in the
V/HCTZ group) were excluded from the intent-
to-treat population due to missing baseline or
post-baseline assessments. Patient disposition
throughout the study is illustrated in Figure 2. Most
of the patients followed the treatment regimen
as prescribed, with the exception of 37 patients
(10 patients in the V-low group, 15 patients in the
V-high group and 12 patients in the V/HCTZ group)
with reported missed doses, titration errors or intake
of prohibited medications. During the study 87% of
patients in the V-low group and 86% of patients in
the V-high group required titration to the next dose
level (level 2 or level 3) as compared with 63% of
patients for V/HCTZ.
Efficacy outcomes
The proportion of patients achieving a BP control
rate o140/90mmHg was higher (Po0.05) for the V/
HCTZ group as compared with the V-low and V-high
group at weeks 2, 4 and 6 (Figure 3). Significant
differences between the V-high group and V-low
group regarding the percentage of patients achieving
the target BP goal of o140/90mmHg at week 4 (46
vs 26%, respectively; Po0.0001), and numerically
higher number of patients achieving the BP goal in
the V-high group at week 6 (51 vs 45%, respectively;
P¼NS) was observed. This was primarily attributed
to the addition of HCTZ. Within each treatment group,
1-28 day
washout
Valsartan80 mg
(V-low)
Valsartan+ HCTZ 160/12.5 mg
Valsartan160 mg
Valsartan+ HCTZ
160/12.5 mg (V/HCTZ)
Valsartan+ HCTZ
160/25 mg
Valsartan160 mg
(V-high)
Valsartan+ HCTZ 160/25 mg
Valsartan+ HCTZ
160/12.5 mg
Valsartan+ HCTZ 160/25 mg
24 6 -4 0
Screening/
Prewash
6-week Double-blind randomization
Weeks
Figure 1 Study design.
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were statistically significant at weeks 2, 4 and 6
(Figures 4a and b). At weeks 2, 4 and 6, the
reduction in the MSSBP and MSDBP were greater
(Po0.01) in the V/HCTZ group as compared with
reductions observed in both V-low and V-high
groups. Change in MSSBP from baseline at week 4
(primary efficacy) was:  15.3±12mmHg for the
V-low group;  22.0±13mmHg for the V-high
group and  26.0±14mmHg for V/HCTZ. At week
6 maximal reduction in SBP from baseline was
observed in the V/HCTZ group ( 27.7±13mmHg)
and was greater (Po0.01) when compared with
that in the V-low ( 21.2±13mmHg, difference¼
1413 Enrolled
652 Randomized
Reasons for discontinuation
￿ Adverse events (6)
￿ Lack of efficacy (5)
￿ Protocol deviation (2)
￿ Withdrawal of consent (4)
V-low
n=218
V/HCTZ
N = 213
Discontinued
N =17
Discontinued
n=17
Intent to treat n=218
Completed n=201
Reasons for discontinuation:
￿ Adverse events (6)
￿ Lack of efficacy (2)
￿ Protocol deviation (1)
￿ Withdrawal of consent (6)
￿ Lost to follow-up (2)
Intent to treat n=210
Completed n=196
V-high
n=221
Discontinued
N =17
Intent to treat n=220
Completed n=204
Reasons for discontinuation
￿ Adverse events (5)
￿ Lack of efficacy (6)
￿ Lost to follow-up (3)
￿ Withdrawal of consent (3)
Figure 2 Patient disposition. V-low refers to patients initiated therapy with valsartan (80mg); V-high refers to patients initiated therapy
with valsartan (160mg) and V/HCTZ refers to patients initiated with combination therapy. V/HCTZ, valsartan/hydrochlorothiazide.
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Figure 3 Percentage of patients achieving the BP goal (o140/
90mmHg). The primary efficacy time point was at week 4. At all
weeks, 2, 4 and 6, the difference in the percentage of patients
achieving BP control between the V/HCTZ and V-low (Po0.001)
and between the V/HCTZ and V-high (Po0.05) groups was
statistically significant. The difference between V-low and V-high
was significant (Po0.001) only at week 4 but not at weeks 2 and 6.
BP, blood pressure; V/HCTZ, valsartan/hydrochlorothiazide;
V-high, valsartan 160mg; V-low, valsartan 80mg.
Table 1 Patient characteristics at baseline during the double-
blind treatment period
Treatment groups
V-low V-high V/HCTZ
n 218 221 213
Age (years) 52.2±10.7 53.1±9 52.6±10.4
X65 years, n (%) 21 (9.6) 25 (11.3) 30 (14.1)
Female, n (%) 99 (45.4) 98 (44.3) 101 (47.4)
Race, n (%)
Caucasian 152 (69.7) 150 (67.9) 137 (64.3)
Black 37 (17.0) 38 (17.2) 39 (18.3)
Hispanic 21 (9.6) 22 (10.0) 23 (10.8)
Previous antihypertensive
medication (last 30 days),
n (%)
108 (49.5) 128 (57.9) 106 (49.8)
BW (kg) 92.7±21 94.2±21 93.2±20
BMI (kgm
 2) 32.0±6.8 32.7±6.4 32.5±6.9
Potassium (mmoll
 1) 4.36±0.5 4.27±0.4 4.29±0.4
Serum creatinine (mgdl
 1) 0.87±0.2 0.89±0.2 0.86±0.2
Glucose (mgdl
 1) 107±38 107±38 107±34
Total cholesterol (mgdl
 1) 205±41 200±44 204±39
LDL-C (mgdl
 1) 121.5±33 119±35 122±32
HDL-C (mgdl
 1) 51.5±14 50.4±13 52.6±14
Triglycerides (mgdl
 1) 161±99 157±127 154±93
Metabolic syndrome, n (%) 125 (57.3) 126 (57.0) 121 (56.8)
Diabetes*, n (%) 23 (10.6) 30 (13.6) 30 (14.1)
Mean sitting BP (mmHg)
Systolic 160.7±7.4 161.1±7.9 161.0±7.8
Diastolic 97.7±5.5 98.2±5.1 98.2±5.1
Stage-2 hypertension,
n (%)
147 (67.4) 148 (67.3) 145 (69.0)
Abbreviations: BMI, body mass index; BP, blood pressure; BW, body
weight; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; V/HCTZ, valsartan/hydrochlorothia-
zide; V-high, valsartan 160mg; V-low, valsartan 80mg.
*Diabetes defined as fasting plasma glucose X126mgdl
 1
(7.0mmoll
 1). Data represented as mean±s.d. unless otherwise noted.
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ence¼3.8mmHg) groups. The reductions in
MSSBP observed in the V-high group were greater
(Po0.05) when compared with those observed with
V-low group during both weeks 4 and 6 (Figure 4a).
The mean reductions in MSDBP from baseline
to week 6 was greater (Po0.001) in the V/HCTZ
group ( 14.6±7mmHg) as compared with that
in the V-low ( 8.5±7mmHg) and V-high groups
( 12.0±10mmHg) (Figure 4b). The reduction from
baseline in MSDBP observed with V-high was
greater (Po0.001) at week 4 ( 7.7±9mmHg) as
compared with V-low.
BP control rates and changes in MSSBP and
MSDBP from baseline to week 6 in subgroups of
patients with stage-1 or stage-2 hypertension were
examined through post hoc analysis. Average base-
line BP in the stage-1 hypertension group was 154/
95mmHg as compared with 164/100mmHg in the
stage-2 hypertension group. BP control rates after 4
weeks of therapy for patients with stage-1 and stage-
2 hypertension were higher (Po0.05) for V/HCTZ
(70 and 52%, respectively) as compared with that
for V-low (38 and 20%, respectively). Reductions in
SBP and DBP were greater in stage-2 as compared
with stage-1 hypertension among the treatment
groups; however, the BP lowering advantage with
V/HCTZ remained (Po0.05) when compared with
V-low and V-high for patients with either stage-1 or
stage-2 hypertension. The systolic and diastolic
BP difference between V/HCTZ and V-low at
week 4 was  9.2/ 6.1mmHg in stage-1 and
 11.7/ 5.9mmHg in stage-2.
Time to BP goal
The mean time to achieve BP goal, defined as first
achievement of the target BP goal of o140/
90mmHg, was significantly improved (Po0.0001)
with V/HCTZ (2.8±0.13 weeks) as compared with
that in the V-high (3.9±0.15 weeks) and V-low
groups (4.3±0.14 weeks) in both stage-1 and stage-2
hypertension (Figure 5). The median time to first
treatment success (that is, the time point at which
50% of patients reached their goal) was 2.0 weeks
(95% confidence interval 2.0, 3.0) in the V/HCTZ
group, compared with 6.0 weeks (95% confidence
interval 4.0, 6.0) in the V-low and 3.0 weeks (95%
confidence interval 3.0, 4.0) in the V-high group.
Adverse events
The three treatment regimens, valsartan (80mg),
valsartan (160mg) and valsartan/HCTZ (160/12.5mg),
were well-tolerated. There were no clinically or
statistically significant differences in the AE rates
among the three groups. Overall, AEs were experi-
enced by 50.5% (110/218) of patients in the V-low
group, 50.7% (112/221) of patients in the V-high
group and 53.1% (113/213) of patients in the
V/HCTZ group. Drug-related AEs were similar
across the three treatment groups for V-low
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Figure 4 Change in (a) MSSBP (mmHg) and (b) MSDBP (mmHg)
from baseline to week 6 of the double-blind treatment period. The
primary efficacy time point was at week 4. At weeks 1, 2, 3, 4 and
6, the reduction in MSSBP and MSDBP was significantly greater
in the V/HCTZ group as compared with the reductions observed
in both V-low (Po0.001) and V-high groups (Po0.01). Reductions
in MSSBP were significantly greater with V-high as compared
with V-low only at weeks 3, 4 and 6 (Po0.001) and reductions in
MSDBP were significantly greater with V-high as compared with
V-low only at weeks 3 and 4 (Po0.001). BP, blood pressure;
MSSBP, mean sitting systolic BP; MSSDP, mean sitting diastolic
BP; V/HCTZ, valsartan/hydrochlorothiazide; V-high, valsartan
160mg; V-low, valsartan 80mg.
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Figure 5 Mean time to BP goal defined as time (weeks) to
achieving first treatment success (BPo140/90mmHg) in patients
with stage-1 and stage-2 hypertension. Po0.05 for the V/HCTZ
group as compared with the V-low and V-high group at week 6.
BP, blood pressure; V/HCTZ, valsartan/hydrochlorothiazide;
V-high, valsartan 160mg; V-low, valsartan 80mg.
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Journal of Human Hypertension(13.8%), V-high (11.8%) and V/HCTZ (14.1%). The
most frequent AEs, experienced by at least 3% of
patients in any treatment group, were headache,
dizziness, fatigue, nausea, diarrhoea, upper respira-
tory tract infection, back pain and myalgia (Table 2).
Most AEs were considered by the investigator to be
of mild or moderate severity and were not suspected
to be treatment-related. AEs associated with low BP,
such as dizziness (including postural dizziness),
vertigo and hypotension (including orthostatic
hypotension), were observed in 5% of patients with
V-low, 9% of patients with V-high and 8% of
patients with V/HCTZ. The incidence of AEs
associated with low BP appeared to be higher for
V/HCTZ and V-high as compared with V-low, but
only three patients in V/HCTZ and V-high reported
symptoms of moderate severity, compared with four
in the V-low group; all else were mild.
Analysis of the most frequent AEs experienced by
at least 5% of patients (headache and dizziness)
showed an overall increased incidence in the first
two weeks of the study compared with 4 and 6 weeks
after therapy was initiated. At week 2, the incidence
of dizziness (overall 2.9%; V-low 2.3%; V-high 2.7%;
V/HCTZ 3.8%) and headache (overall 4.6%; V-low
5.5%; V-high 5.9%; V/HCTZ 2.3%) were higher
compared with those observed at week 4 (dizziness:
overall 2.3%; V-low 0.9%; V-high 3.1%; V/HCTZ
2.8% and headache: overall 1.5%; V-low 2.3%;
V-high 1.4%; V/HCTZ 0.9%) and week 6 (dizziness:
overall 0.9%; V-low 1.4%; V-high 1.8%; V/HCTZ
0.5% and headache: overall 0.5%; V-low 0.5%;
V-high 0.5%; V/HCTZ 0.5%).
There were no significant changes in any of the
laboratory measures from baseline, including serum
creatinine, glucose or lipid levels, during the study,
except potassium levels (Table 3). Potassium levels
decreased in all the groups, with significantly greater
reductions (Po0.05) for V/HCTZ ( 0.19mmoll
 1)a s
compared with V-low ( 0.09mmoll
 1)
Serious AEs were experienced by five patients
(2.3%) in the V-low group, three patients (1.4%) in
the V-high group and five patients (2.3%) in the
V/HCTZ group. Seventeen (2.6%) patients experi-
enced AEs or SAEs, causing discontinuation from
the study: 6 (2.8%) in the V-low, 5 (2.3%) in the
V-high and 6 (2.8%) in the V/HCTZ group.
Suspected AEs leading to withdrawal from the
study included dizziness, headache, anxiety,
asthenia, fatigue and nausea, and were distributed
among the three treatment groups. There were no
drug discontinuations for hypotension in the study.
There were no deaths reported in this study.
Discussion
Although evidence from clinical trials suggests that
BP reduction to goal is crucial in reducing CV
outcomes, at least half of all hypertensives remain
untreated, with most of those that are treated
requiring combination therapy to achieve the target
BP control rate.
1,6 Results from this study suggest
that for patients with stage-1 and stage-2 hyperten-
sion, initiating treatment with combination therapy
using the ARB, valsartan and low-dose HCTZ (160/
12.5mg and increasing the dose to 160/25mg if
needed) provided greater benefit in reaching BP
control rates compared with initiating treatment
with low- or high-dose valsartan monotherapy. The
study demonstrated that by initiating therapy with
two antihypertensive medications and titrating the
dose every 2 weeks, if required, will lead to more
effective BP control rates in a shorter period of time
as compared with initiating treatment by monother-
apy. After only 4 weeks of therapy, 58% of patients
on the initial combination agent achieved BP control
as compared with only 26% initiated with valsartan
(80mg). Furthermore, AEs between V/HCTZ and the
two valsartan monotherapy arms were similar,
confirming the excellent tolerability achieved with
Table 2 Most frequent AEs
V-low
(n¼218)
V-high
(n¼221)
V/HCTZ
(n¼213)
Patients with AEs, n (%) 110 (50.5) 112 (50.7) 113 (53.1)
Suspected AEs related to
study drug, n (%)
30 (13.8) 26 (11.8) 30 (14.1)
AEs leading to
discontinuation, n (%)
6 (2.8) 5 (2.3) 6 (2.8)
AE preferred term, n (%)
Headache 18 (8.3) 17 (7.7) 10 (4.7)
Dizziness
a 11 (5.0) 20 (9.0) 17 (8.0)
Fatigue 10 (4.6) 7 (3.2) 8 (3.8)
Nausea 8 (3.7) 7 (3.2) 9 (4.2)
Diarrhoea 8 (3.7) 5 (2.3) 8 (3.8)
Upper respiratory tract
infection
5 (2.3) 7 (3.2) 7 (3.3)
Back pain 0 (0.0) 3 (1.4) 7 (3.3)
Myalgia 7 (3.2) 2 (0.9) 1 (0.5)
Abbreviation: AE, adverse event.
aThe term dizziness includes any term associated with low BP, such as
postural dizziness, hypotension, orthostatic hypotension and vertigo.
Table 3 Blood chemistry measures after 6 weeks of treatment:
change from baseline
Treatment groups
V-low V-high V/HCTZ
Potassium (mmoll
 1)  0.09±0.5* 0.11±0.4* 0.19±0.4*
w
Serum creatinine (mgdl
 1) 0.02±0.1 0.04±0.2 0.04±0.1
Glucose (mgdl
 1) 4.2±23 2.3±30 1.0±24
Total cholesterol (mgdl
 1)  4.5±28  1.4±29 0.3±29
LDL-C (mgdl
 1)  5.9±23  3.9±27  1.9±23
HDL-C (mgdl
 1)  0.6±6  0.6±6  1.3±8
Triglycerides (mgdl
 1) 9.6±78 13.7±72 20.1±98
Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C,
low-density lipoprotein cholesterol; V/HCTZ, valsartan/hydrochlor-
othiazide; V-high, valsartan 160mg; V-low, valsartan 80mg.
*Po0.05 vs baseline;
wPo0.05 vs V-low.
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associated with excessive drops in BP in V/HCTZ
were also not observed, as noted by similar
incidences of AEs related to low BP and hypotensive
episodes among the three groups during the study.
The preliminary concern of ‘over-treatment’ in the
V/HCTZ group was also not observed, since over
85% of patients initiated on valsartan monotherapy
required add-on HCTZ therapy.
In the Valsartan Antihypertensive Long-term Use
Evaluation (VALUE) study, which compared the CV
outcomes of 15314 eligible patients randomized to a
valsartan or an amlodipine-based treatment, higher
odds ratios in favour of amlodipine were noted for
all endpoints during the first 6 months, when BP
differences between the treatment groups were
greatest.
12 The starting dose of valsartan in the
VALUE trial was 80mg. Patients remained on the
valsartan 80-mg dose for at least 1 month (4 weeks)
before being up-titrated to the next step in the
protocol. In our current study, initiating treatment
with higher dose valsartan monotherapy (160mg)
was associated with higher BP control rates and a
shortened time to reach BP control as compared
with low-dose valsartan (80mg) monotherapy, but
the BP differences were largely influenced by
addition of low-dose HCTZ at week 4 (Figure 4).
Perhaps the early outcomes of the VALUE trial were
not favourable for valsartan as the trial not only
underestimated the proportion of patients requiring
combination therapy, but also underutilized the
add-on of HCTZ (40% of patients in the trial stayed
on valsartan monotherapy, with only 70% of those
patients having their BP controlled).
Studies with initial combination therapy using an
ARB and low-dose HCTZ have demonstrated super-
ior BP control rates and BP-lowering efficacy as
compared with initiating therapy with monotherapy
in patients with stage-2 hypertension or dia-
betes.
4,5,13–16 There is a consensus that initial
combination therapy works for high-risk patients
with stage-2 hypertension; however, this does not
have current support as an optional treatment
approach for wider use in primary hypertension.
11
Evidence supporting initial use of combination therapy
for patients with stage-1 hypertension largely comes
from recent findings from the ACCOMPLISH study.
17
Over 9000 patients with stage-1 or stage-2 hyper-
tension were initiated with ACE-inhibitorþHCTZ or
ACE-inhibitorþamlodipine combination therapy. The
study demonstrated that use of initial combination
therapy was very effective and safe for both stage-1 and
stage-2 hypertension, as it reported some of the highest
BP control rates for any large outcomes study.
18
One of the clinical challenges with treating a
multifactorial disease like hypertension is that it is
very difficult to predict an individual’s response to
any given treatment. An individual’s response to
therapy is not only influenced by baseline factors,
such as activity of the renin–angiotensin system and
sodium intake, but is also affected by the patient’s
compensatory response to the therapy in an attempt
to prevent further lowering BP. Using two well-
tolerated antihypertensive agents with complemen-
tary modes of action to reduce BP will act to limit
the counter-regulatory response and thus ensure
effective antihypertensive response in a majority of
patients.
19 Initiating antihypertensive therapy for
patients with stage-1 and stage-2 hypertension,
using a well-tolerated combination agent such as
an ACE-inhibitor or ARB and low-dose diuretic, is
perhaps a more effective approach to enable more
patients in the primary care setting to reach the BP
goal.
17 A recent study adopted this treatment
approach in primary care offices where patients
were initiated with combination therapy using a
renin–angiotensin system blocker (ACE inhibitor or
ARB) and low-dose diuretic as compared with the
conventional guideline treatment approach of start-
ing with monotherapy.
20 The study demonstrated
excellent tolerability and superior BP control rates
using initial combination therapy as compared with
those patients who were started with monotherapy
and titrated upwards following established treat-
ment guidelines. Thus there is good evidence to
recommend wide use of combination agents as first-
line therapy for hypertensive patients, regardless of
their baseline BP, in the clinical practice setting.
Study limitations
This study was not designed to demonstrate the
complete treatment strategy approach for using
a valsartan-based regimen, as it did not allow
achievement of the maximum antihypertensive
effect. The study did not include the maximum
dose of valsartan (320mg) in combination with
HCTZ, was of 6 weeks duration and the dose
titration period was only 2 weeks. The study, rather,
was designed to test the efficacy and tolerability of
using initial combination therapy for patients with
primary stage-1 and stage-2 hypertension.
In conclusion, initial use of combination therapy
using a renin–angiotensin system blocker and low-
dose diuretic in the standard treatment of hyperten-
sion in the primary care setting is an idea whose
time has not yet come but which finds support in
this study. In this study, initiating therapy with
valsartan and low-dose HCTZ (160/12.5mg) resulted
in higher BP control rates, greater antihypertensive
effect and prompt BP control with no significant
increase in AEs in patients with stage-1 or stage-2
hypertension. The study has provided a template
one could follow for treating hypertension
effectively and safely using initial combination
therapy, including uncomplicated cases of stage-1
to stage-2 hypertension. This study has demon-
strated that initial combination therapy with an ARB
and low-dose diuretic should become routine for
treatment of hypertension, thereby improving BP
control rates for patients with primary, essential
hypertension.
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